Screening of Lactobacillus spp. for the prevention of Pseudomonas aeruginosa pulmonary infections

BMC Microbiology

Gwenaelle Le Blay¹  Georges Barbier³  Rozenn Le Berre²  Youenn Alexandre⁴ 

[1] Université de Brest, CNRS, IFREMER, UMR 6197-Laboratoire de Microbiologie des Environnement Extrêmes (LMEE), Institut Universitaire Européen de la Mer, Place Nicolas Copernic, Technopôle Brest-Iroise, 29280 Plouzané, France;Département de Médecine Interne et Pneumologie, CHRU La Cavale-Blanche, 29200 Brest, France;Université de Brest, EA 3882-Laboratoire Universitaire de Biodiversité et d’Écologie Microbienne (LUBEM), Parvis Blaise Pascal, Technopôle Brest-Iroise, 29280 Plouzané, France;Université de Brest, EA 3882-Laboratoire Universitaire de Biodiversité et d’Écologie Microbienne (LUBEM), Faculté de Médecine, 22 avenue Camille Desmoulins, 29200 Brest, France

关键词: Elastolytic activity;    Biofilm formation;    Organic acids;    Probiotics;    Lactobacillus;    Pseudomonas aeruginosa;   

Others  :  1141285
DOI  :  10.1186/1471-2180-14-107

 received in 2014-02-13, accepted in 2014-04-22,  发布年份 2014

【 摘 要 】

Background

Pseudomonas aeruginosa is an opportunistic pathogen that significantly increases morbidity and mortality in nosocomial infections and cystic fibrosis patients. Its pathogenicity especially relies on the production of virulence factors or resistances to many antibiotics. Since multiplication of antibiotic resistance can lead to therapeutic impasses, it becomes necessary to develop new tools for fighting P. aeruginosa infections. The use of probiotics is one of the ways currently being explored. Probiotics are microorganisms that exert a positive effect on the host’s health and some of them are known to possess antibacterial activities. Since most of their effects have been shown in the digestive tract, experimental data compatible with the respiratory environment are strongly needed. The main goal of this study was then to test the capacity of lactobacilli to inhibit major virulence factors (elastolytic activity and biofilm formation) associated with P. aeruginosa pathogenicity.

Results

Sixty-seven lactobacilli were isolated from the oral cavities of healthy volunteers. These isolates together with 20 lactobacilli isolated from raw milks, were tested for their capacity to decrease biofilm formation and activity of the elastase produced by P. aeruginosa PAO1. Ten isolates, particularly efficient, were accurately identified using a polyphasic approach (API 50 CHL, mass-spectrometry and 16S/rpoA/pheS genes sequencing) and typed by pulsed-field gel electrophoresis (PFGE). The 8 remaining strains belonging to the L. fermentum (6), L. zeae (1) and L. paracasei (1) species were sensitive to all antibiotics tested with the exception of the intrinsic resistance to vancomycin. The strains were all able to grow in artificial saliva.

Conclusion

Eight strains belonging to L. fermentum, L. zeae and L. paracasei species harbouring anti-elastase and anti-biofilm properties are potential probiotics for fighting P. aeruginosa pulmonary infections. However, further studies are needed in order to test their innocuity and their capacity to behave such as an oropharyngeal barrier against Pseudomonas aeruginosa colonisation in vivo.

【 授权许可】

   
2014 Alexandre et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Gaynes R, Edwards JR: Overview of nosocomial infections caused by Gram-negative bacilli. Clin Infect Dis 2005, 41:848-854.
• [2]Fujitani S, Sun H-Y, Yu VL, Weingarten JA: Pneumonia due to Pseudomonas aeruginosa. Part I: epidemiology, clinical diagnosis, and source. Chest 2011, 139:909-919.
• [3]Rajan S, Saiman L: Pulmonary infections in patients with cystic fibrosis. Semin Respir Infect 2002, 17:47-56.
• [4]Sadikot RT, Blackwell TS, Christman JW, Prince AS: Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med 2005, 171:1209-1223.
• [5]Le Berre R, Nguyen S, Nowak E, Kipnis E, Pierre M, Quenee L, Ader F, Lancel S, Courcol R, Guery BP, Faure K: Relative contribution of three main virulence factors in Pseudomonas aeruginosa pneumonia. Crit Care Med 2011, 39:2113-2120.
• [6]Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg EP: Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 2000, 407:762-764.
• [7]Guinane CM, Cotter PD: Role of gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ. Ther Adv Gastroenterol 2013, 6:295-308.
• [8]Wang Z, Yang Y: Upper gastrointestinal microbiota and digestive diseases. World J Gastroenterol 2013, 19:1541-1550.
• [9]Round JL, Mazmanian SK: The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009, 9:313-323.
• [10]Meurman JH: Probiotics: do they have a role in oral medicine and dentistry? Eur J Oral Sci 2005, 113:188-196.
• [11]Siempos II, Ntaidou TK, Falagas ME: Impact of the administration of probiotics on the incidence of ventilator-associated pneumonia: a meta-analysis of randomized controlled trials. Crit Care Med 2010, 38:954-962.
• [12]Hao Q, Lu Z, Dong BR, Huang CQ, Wu T: Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev 2011, CD006895.
• [13]Delavenne E, Mounier J, Déniel F, Barbier G, Le Blay G: Biodiversity of antifungal lactic acid bacteria isolated from raw milk samples from cow, ewe and goat over one-year period. Int J Food Microbiol 2012, 155:185-190.
• [14]Felis GE, Dellaglio F: Taxonomy of lactobacilli and bifidobacteria. Curr Issues Intest Microbiol 2007, 8:44-61.
• [15]Alakomi H-LL, Skyttä E, Saarela M, Mattila-Sandholm T, Latva-Kala K, Helander IM: Lactic acid permeabilizes gram-negative bacteria by disrupting the outer membrane. Appl Environ Microbiol 2000, 66:2001-2005.
• [16]Phillips I, Lobo AZ, Fernandes R, Gundara NS: Acetic acid in the treatment of superficial wounds infected by Pseudomonas aeruginosa. Lancet 1968, 1:11-14.
• [17]Crouch Brewer S, Wunderink RG, Jones CB: Leeper K V: Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest 1996, 109:1019-1029.
• [18]Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW: Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995, 151:1075-1082.
• [19]Alexandre Y, Le Blay G, Boisramé-Gastrin S, Le Gall F, Héry-Arnaud G, Gouriou S, Vallet S, Le Berre R: Probiotics: a new way to fight bacterial pulmonary infections? Médecine Mal Infect 2013, 44:9-17.
• [20]Petrof EO: Probiotics and gastrointestinal disease: clinical evidence and basic science. Antiinflamm Antiallergy Agents Med Chem 2009, 8:260-269.
• [21]Barraud D, Blard C, Hein F, Marçon O, Cravoisy A, Nace L, Alla F, Bollaert P-E, Gibot S: Probiotics in the critically ill patient: a double blind, randomized, placebo-controlled trial. Intensive Care Med 2010, 36:1540-1547.
• [22]Dewhirst FE, Chen T, Izard J, Paster BJ, Tanner ACR, Yu W-H, Lakshmanan A, Wade WG: The human oral microbiome. J Bacteriol 2010, 192:5002-5017.
• [23]Colloca M, Ahumada M, López M, Nader-Macías M: Surface properties of lactobacilli isolated from healthy subjects. Oral Dis 2008, 6:227-233.
• [24]Teanpaisan R, Dahlén G: Use of polymerase chain reaction techniques and sodium dodecyl sulfate-polyacrylamide gel electrophoresis for differentiation of oral Lactobacillus species. Oral Microbiol Immunol 2006, 21:79-83.
• [25]Ahrné S, Nobaek S, Jeppsson B, Adlerberth I, Wold A, Molin G: The normal Lactobacillus flora of healthy human rectal and oral mucosa. J Appl Microbiol 1998, 85:88-94.
• [26]Dal Bello F, Hertel C: Oral cavity as natural reservoir for intestinal lactobacilli. Syst Appl Microbiol 2006, 29:69-76.
• [27]Maukonen J, Mättö J, Suihko M-L, Saarela M: Intra-individual diversity and similarity of salivary and faecal microbiota. J Med Microbiol 2008, 57:1560-1568.
• [28]Caufield PW, Li Y, Dasanayake A, Saxena D: Diversity of lactobacilli in the oral cavities of young women with dental caries. Caries Res 2007, 41:2-8.
• [29]Meurman JH, Stamatova I: Probiotics: contributions to oral health. Oral Dis 2007, 13:443-451.
• [30]Kon Y, Tsukada H, Hasegawa T, Igarashi K, Wada K, Suzuki E, Arakawa M, Gejyo F: The role of Pseudomonas aeruginosa elastase as a potent inflammatory factor in a rat air pouch inflammation model. FEMS Immunol Med Microbiol 1999, 25:313-321.
• [31]Azghani AO, Bedinghaus T, Klein R: Detection of elastase from Pseudomonas aeruginosa in sputum and its potential role in epithelial cell permeability. Lung 2000, 178:181-189.
• [32]Rumbaugh KP, Griswold JA, Hamood AN: The role of quorum sensing in the in vivo virulence of Pseudomonas aeruginosa. Microbes Infect 2000, 2:1721-1731.
• [33]Smith RS, Iglewski BH: Pseudomonas aeruginosa quorum sensing as a potential antimicrobial target. J Clin Invest 2003, 112:1460-1465.
• [34]Montalto M, Vastola M, Marigo L, Covino M, Graziosetto R, Curigliano V, Santoro L, Cuoco L, Manna R, Gasbarrini G: Probiotic treatment increases salivary counts of lactobacilli: a double-blind, randomized, controlled study. Digestion 2004, 69:53-56.
• [35]Danielsen M, Wind A: Susceptibility of Lactobacillus spp to antimicrobial agents. Int J Food Microbiol 2003, 82:1-11.
• [36]Holloway BW: Genetic recombination in Pseudomonas aeruginosa. J Gen Microbiol 1955, 13:572-581.
• [37]Hartemink R, Domenech V, Rombouts F: LAMVAB—A new selective medium for the isolation of lactobacilli from faeces. J Microbiol Methods 1997, 29:77-84.
• [38]Héry-Arnaud G, Rouzic N, Doloy A, Le Lay G, Garré M, Payan C, Poyart C: Streptococcus australis meningitis. J Med Microbiol 2011, 60:1701-1704.
• [39]Naser SM, Thompson FL, Hoste B, Gevers D, Dawyndt P, Vancanneyt M, Swings J: Application of multilocus sequence analysis (MLSA) for rapid identification of Enterococcus species based on rpoA and pheS genes. Microbiology 2005, 151:2141-2150.
• [40]Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S: MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 2011, 28:2731-2739.
• [41]Delavenne E, Ismail R, Pawtowski A, Mounier J, Barbier G, Le Blay G: Assessment of lactobacilli strains as yogurt bioprotective cultures. Food Control 2013, 30:206-213.
• [42]Merritt JH, Kadouri DE, O’Toole GA, Toole GAO: Growing and analyzing static biofilms. Curr Protoc Microbiol 2005, 00:1B.1.1-1B.1.17.
• [43]Valdéz JC, Peral MC, Rachid M, Santana M, Perdigón G: Interference of Lactobacillus plantarum with Pseudomonas aeruginosa in vitro and in infected burns: the potential use of probiotics in wound treatment. Clin Microbiol Infect 2005, 11:472-479.
• [44]Rust L, Messing CR, Iglewski BH: Elastase assays. Methods Enzymol 1994, 235:554-562.
• [45]Soussy CJ, Bonnet R, Caron F, Cavallo JD, Chardon H, Chidiac C, Courvalin P, Drugeon H, Dubreuil L, Jarlier V, Jehl F, Lambert T, Leclercq R, Nicolas-Chanoine MH, Plesiat P, Ploy MC, Quentin C, Varon E, Weber P: Comité de l’antibiogramme de la société française de microbiologie. Recommandations 2012, 2012:59p.
• [46]Roger P, Delettre J, Bouix M, Béal C: Characterization of Streptococcus salivarius growth and maintenance in artificial saliva. J Appl Microbiol 2011, 111:631-641.